Close Menu

NEW YORK – Natera said this week that it has launched a multi-site prospective study to externally validate a new algorithm for its Prospera donor-derived cell-free DNA transplant rejection test. The PEDAL (Prospera Test Enhancement by Detecting Background Cell-Free DNA Levels) study will enroll 500 kidney transplant patients at 20 major centers in the US and will start recruitment soon.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A study of families explores how children transmit SARS-CoV-2, according to the Associated Press.

US Agricultural Research Service scientists have sequenced the genome of the Asian giant hornet.

According to the Economist, pooled testing for COVID-19 could help alleviate strains on testing labs.

In Science this week: MIT researchers outline approach dubbed translatable components regression to predict treatment response among IBD patients.